1446421-13-1

Basic information

• Product Name: N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-2-morpholinoacetamide
• Synonyms: N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-2-morpholinoacetamide
• CAS NO: 1446421-13-1
• Molecular Weight: 494.421
• Mol File: 1446421-13-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-2-morpholinoacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-2-morpholinoacetamide(1446421-13-1)
• EPA Substance Registry System: N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-2-morpholinoacetamide(1446421-13-1)

Safety Data

• Hazardous Substances Data: 1446421-13-1(Hazardous Substances Data)

Upstream product

• 2067-58-5 4-amino-N,N-bis(2-chloroethyl)aniline 
• 17329-87-2 2-chloro-N-(4-nitro-phenyl)-acetamide 
• 100-01-6 4-nitro-aniline 
• 262368-13-8 2-morpholin-4-yl-N-(4-nitro-phenyl)-acetamide 
• 105076-76-4 N-(4-amino-phenyl)-2-(morpholin-4-yl)-acetamide 
• 82484-59-1 4-bis-(β-chloroethyl)aminophenyl isocyanate 

Relevant articles and documents

Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach

A series of new, water-soluble phenyl N-mustard-benzenealkylamide conjugates containing hydrophilic ω-dialkylaminoalkylamide or ω-cyclic aminoalkylamide moieties were synthesized via a bioisostere approach. These compounds have a broad spectrum of antitumor activity against a panel of human tumor cell lines. Of these derivatives, compound 18b effectively suppressed the growth of colon cancer (HCT-116), prostate cancer (PC3), and lung cancer (H460) xenografts. The growth of HCT-116 xenografts was almost completely suppressed when co-treated with compound 18b and 5-fluorouracil. Furthermore, compound 18b can induce DNA cross-linking and cell-cycle arrest at the G2/M phase. Early preclinical studies, including pharmacokinetics in rats, inhibition of the hERG, and 14 days of acute intravenous injection toxicity, suggest that compound 18b is a promising candidate for further preclinical studies.